Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Montelukast 10 Mg Oral Tablet, placebo.
- Who it may be relevant to
- Registry conditions: Acute Myocardial Infarction (AMI). Basic parameters: 30 years — 75 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction: A Randomized Controlled Trial
Overview
This is a randomized controlled clinical trial designed to evaluate the therapeutic effects of Montelukast in patients diagnosed with Acute Myocardial Infarction (AMI). The study aims to investigate whether the administration of Montelukast influences inflammatory markers and the extent of cardiac injury following a heart attack.Participants will be randomly assigned to receive either the active medication or a placebo to provide high-quality evidence regarding the drug's potential cardioprotective and anti-inflammatory properties. The trial is conducted through the Faculty of Pharmacy and Faculty of Medicine at Mansoura University
Interventions
- Drug Montelukast 10 Mg Oral Tablet
Montelukast 10 Mg Oral Tablet - Other placebo
placebo
Primary outcome measures
- Change in inflammatory biomarkers (IL-6, TNF-α, hs-CRP, Galectin-3, LTB4) [Time frame: Baseline, Day 3, and Week 4]
Eligibility criteria
Inclusion criteria
- Age 30-75 years Diagnosed with STEMI within 6 hours of symptom onset Undergoing PCI or thrombolysis Eligible for standard ACS therapy signed Informed consent
Exclusion criteria
- Chronic use of anti-inflammatory drugs
- Severe hepatic or renal impairment
- Hypersensitivity to Montelukast
- Autoimmune or inflammatory diseases
- Cardiogenic shock, severe heart failure or structural complications such as papillary muscle rupture
- Having received cardiopulmonary resuscitation
- Severe and inadequately controlled hypertension
- History of myocardial infarction
- Concomitant active bleeding or visceral hemorrhage
- Concomitant malignant tumors, lymphomas, leukemias, or other diseases
- gastrointestinal surgery within the past 4 weeks that may affect the absorption of the investigational drug
- Family history of psychiatric disorders
- Pregnancy or lactation
- Participation in another clinical trial
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Other
Study locations
Egypt · 1 center
- Mansoura Faculty of Medicine hospital — Al Mansurah
Identifiers
NCT: NCT07537868 · MDP.25.09.191